{"prompt": "['Study Number: GSP 301-305', 'Version 3.0', 'Date 18-Jul-2018', 'Change from baseline in AM subject-reported iTNSS over the 14-day treatment period.', 'Change from baseline in PM subject-reported ITNSS over the 14-day treatment period.', 'Change from baseline in PM subject-reported iTNSS over the 14-day treatment period.', 'Change from baseline in subject-reported reflective individual nasal symptoms over the 14-day', 'treatment period (AM, PM and average of AM and PM).', 'Change from baseline in subject-reported instantaneous individual nasal symptoms over the', '14-day treatment period (AM, PM and average of AM and PM).', 'Change from baseline in average AM and PM subject-reported rTNSS and iTNSS for each day.', 'Change from baseline in AM subject-reported rTNSS and iTNSS for each day.', 'Change from baseline in PM subject-reported rTNSS and iTNSS for each day.', 'Ocular symptoms:', 'Change from baseline in average AM and PM subject-reported instantaneous Total Ocular', 'Symptom Score (iTOSS) over the 14-day treatment period.', 'Change from baseline in AM subject-reported rTOSS over the 14-day treatment period.', 'Change from baseline in AM subject-reported iTOSS over the 14-day treatment period.', 'Change from baseline in PM subject-reported rTOSS over the 14-day treatment period.', 'Change from baseline in PM subject-reported iTOSS over the 14-day treatment period.', 'Change from baseline in subject-reported reflective individual ocular symptoms over the 14-day', 'treatment period (AM, PM, and average AM and PM).', 'Change from baseline in subject-reported instantaneous individual ocular symptoms over the', '14-day treatment period (AM, PM, and average AM and PM).', 'Change from baseline in average of the AM and PM subject-reported rTOSS and iTOSS for each', 'day.', 'Change from baseline in AM subject-reported rTOSS and iTOSS for each day.', 'Change from baseline in PM subject-reported rTOSS and iTOSS for each day.', 'Non-nasal symptoms will be assessed in a similar manner to the ocular symptoms above (as described in the', 'Statistical Analysis Plan [SAP]).', 'Physician assessed Nasal Symptom Score:', 'Change from baseline in physician assessed nasal symptom score (PNSS) and physician assessed', 'individual nasal symptoms at Day 15 (Visit 4).', 'Pediatric Rhinoconjuntivitis Quality of Life Questionnaire:', 'Change from baseline in individual domains of the PRQLQ at Day 15.', 'Number of subjects (planned): A total of approximately 450 subjects (225 subjects randomized to each', 'treatment group) are planned to be randomized in the study.', 'Main criteria for inclusion:', 'Subjects eligible for enrolment in the study must meet all of the following criteria:', '1.', 'Male or non-pregnant female subjects aged >6 to <12 years, at the Screening Visit (Visit 1).', '2.', 'Signed informed consent/assent form (subject and parent/caregiver/legal guardian), which meets all criteria', 'of the current Food and Drug Administration/local regulations.', '3. Documented clinical history of SAR (for at least 2 years preceding the Screening Visit [Visit 1]) with', 'exacerbations (clinical evidence of active symptoms) during the spring or fall allergy seasons for the', 'relevant seasonal allergen (eg, tree/grass pollen or ragweed pollen). SAR must have been of sufficient', 'Glenmark', 'CONFIDENTIAL', 'Page 5 of 90']['Study Number: GSP 301-305', 'Version 3.0', 'Date 18-Jul-2018', \"severity to have required treatment (either continuous or intermittent) in the past, and in the Investigator's\", 'judgment, is expected to require treatment throughout the study period.', '4.', 'Demonstrated sensitivity to at least I seasonal allergen (eg, tree/grass pollen or ragweed pollen) known to', 'induce SAR through a documented positive skin prick lest (wheal diameter at least 5 mm greater than the', 'negative control) to a relevant seasonal allergen. Documentation of a positive result within 12 months', \"prior to the Screening Visit (Visit 1) is acceptable. The subject's positive allergen must be consistent with\", 'the medical history of SAR. Additionally, the subject is expected to be adequately exposed to the SAR', 'allergen that he/she has tested positive for the entire duration of the study.', '5. A 12-hour reflective Total Nasal Symptom Score (rTNSS) value of >6 (out of a possible 12) for the', 'morning (AM) assessment at the Screening Visit (Visit 1).', '6.', 'General good health and free of any disease or concomitant treatment that could interfere with the', 'interpretation of study results, as determined by the Investigator.', '7.', 'Able to demonstrate the correct NS application technique (with the help of Jarents/guardians/caregivers, if', 'needed) at the Screening Visit (Visit 1).', '8.', 'Willing and able to comply with all aspects of the protocol (with the help of parents/guardians/caregivers,', 'if needed).', 'Main criteria for exclusion:', 'Subjects meeting any of the following criteria must not be enrolled in the study:', '1. Eligible females of childbearing potential who are known to be sexually active or pregnant, will be', 'excluded and referred for appropriate evaluation. If a girl has reached puberty and achieved menarche (as', 'determined by the Investigator), parents/guardians/caregivers will be consulted to obtain consent for', 'pregnancy testing and permission to counsel the subject followed by counselling the subject by the', 'Investigator regarding the possible unknown risks associated with study medication during pregnancy.', 'Urine pregnancy test must be negative at the Screening Visit (Visit 1). Male subjects who are known to be', 'sexually active will also be excluded.', '2.', 'Plans to travel outside the known pollen area for the investigational site for 24 hours or longer during the', 'last 7 days of the screening/run-in period.', '3. Plans to travel outside the known pollen area for the investigational site for 2 or more consecutive days OR', '3 or more days in total between the Randomization Visit (Visit 2) and the Final Treatment Visit (Visit 4).', '4.', \"History of significant (based on Investigator's judgement) atopic dermatitis or rhinitis medicamentosa\", '(within 60 days prior to the Screening Visit [Visit 1]).', '5. Treatment with any known strong cytochrome P450 (CYP)3A4 inducers (eg, carbamazepine, phenytoin,', 'rifabutin, rifampin, pioglitazone etc.) or strong inhibitors (eg, azole antifungals, macrolide antibiotics)', 'within 30 days prior to the Screening Visit (Visit 1), or during the study.', '6. Non-vaccinated exposure to or active infection with chickenpox or measles within the 21 days preceding', 'Screening Visit (Visit 1).', '7.', 'A known hypersensitivity to any corticosteroids or antihistamines or to either of the drug components of', 'the Investigational Product or its excipients.', '8.', 'History of anaphylaxis and/or other severe local reaction(s) to skin testing.', '9. Any history or current use of alcohol or drug dependence at the Screening Visit (Visit 1), as determined by', 'the Investigator.', '10. History of positive test for human immune deficiency virus, Hepatitis B or Hepatitis C infection', '(parents/guardians/caregivers will be consulted to obtain consent).', '11. History and evidence of acute or significant chronic sinusitis or chronic purulent post-nasal drip at the', 'Screening Visit (Visit 1).', 'Glenmark', 'CONFIDENTIAL', 'Page 6 of 90']\n\n###\n\n", "completion": "END"}